P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)

Uri Weinberg; Ori Farber; Moshe Giladi; Zeev Bomzon; Eilon Kirson

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)

【24h】

P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)

机译：Lunar - TTFIELD与PD-1抑制剂或多西紫杉醇组合的TTFIELS的第3期试验，用于非小细胞肺癌（NSCLC）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 》 |2017年第1期| 共2页
作者
Uri Weinberg; Ori Farber; Moshe Giladi; Zeev Bomzon; Eilon Kirson;
展开▼
作者单位

Novocure GmbH;

Novocure Ltd.;

Novocure Ltd.;

Novocure Ltd.;

Novocure Ltd.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) [J] . Uri Weinberg, Ori Farber, Moshe Giladi, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017 ,第1期

机译：Lunar - TTFIELD与PD-1抑制剂或多西紫杉醇组合的TTFIELS的第3期试验，用于非小细胞肺癌（NSCLC）
2. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009 ,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
3. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009 ,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
4. Diagnosis of lymph node metastasis in non-small-cell lung cancer (NSCLC) patient on F-18-FDG PET/CT [C] . Tsu-Chi Cheng, Nan-Tsing Chiu, Ting-Yu Su, International Forum on Medical Imaging in Asia 2019 . 2019

机译：F-18-FDG PET / CT诊断非小细胞肺癌（NSCLC）淋巴结转移
5. Use of Palliative Radiotherapy Among Metastatic Non-small-cell Lung Cancer (NSCLC) Patients in Puerto Rico [D] . ?Quinones Avila, Valerie 2020

机译：在波多黎各的转移性非小细胞肺癌（NSCLC）患者中使用姑息放射治疗
6. Editors choice: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) [O] . G. R. Blumenschein Jr, E. F. Smit, D. Planchard, -1

机译：编辑选择：MEK1 / MEK2抑制剂曲美替尼（GSK1120212）与多西他赛相比在KRAS突变晚期非小细胞肺癌（NSCLC）中的II期随机研究
7. P2-291: Results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC) [O] . Novello Silvia, Tibaldi Carmelo, Scagliotti Giorgio V., 2007

机译：P2-291：一项多中心紫杉醇（D）和吉西他滨（G）和顺铂/吉西他滨（CG）两种不同组合的多中心随机II期试验的结果，然后多西紫杉醇作为局部晚期或转移性非小细胞肺癌的一线治疗癌症（NSCLC）

P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅